Azaprostacyclins, their preparation and pharmaceutical use
    71.
    发明授权
    Azaprostacyclins, their preparation and pharmaceutical use 失效
    阿沙普罗环素,其制备和药物用途

    公开(公告)号:US4567195A

    公开(公告)日:1986-01-28

    申请号:US591719

    申请日:1984-03-21

    摘要: Azaprostacyclins of Formula I ##STR1## wherein R.sub.1 is hydrogen, alkyl, cycloalkyl, aryl, a heterocyclic residue, or a phenacyl residue optionally substituted on the phenyl ring by bromine, phenyl, alkoxy, or dialkoxy,W is a free or functionally modified carbonyl group or a ##STR2## wherein R.sub.8 is hydrogen or alkyl of 1-5 carbon atoms and R.sub.9 is hydrogen or a readily cleavable ether or acyl residue and wherein the OR.sub.9 -group can be in the .alpha.- or .beta.-position,R.sub.2 is a free or functionally modified hydroxy group,R.sub.3 and R.sub.4 each independently is hydrogen, alkyl of 1-5 carbon atoms, or fluorine,D is alkylene of 1-2 carbon atoms which can be substituted by alkyl groups of 1-5 carbon atoms,R.sub.5 is hydrogen or alkyl of 1-2 carbon atoms or, when D is alkylene of 1 or 2 carbon atoms, R.sub.5, together with R.sub.6, represents a bond,R.sub.6 and R.sub.7 each independently is hydrogen or alkyl of 1-2 carbon atoms, whereinR.sub.6 (R.sub.7) is halogen when R.sub.7 (R.sub.6), respectively, is alkyl of 1-2 carbon atoms orR.sub.5 and R.sub.7 each independently is hydrogen or alkyl of 1-2 carbon atoms whenD and R.sub.6 together form a carbocyclic ring closed via (CH.sub.2).sub.1-3 with D as --CH

    摘要翻译: 式I的阿沙普罗环素其中R 1是氢,烷基,环烷基,芳基,杂环残基或任选在苯环上被溴,苯基,烷氧基或二烷氧基取代的苯甲酰甲基残基,W是游离或 官能改性的羰基或其中R8是氢或1-5个碳原子的烷基,R9是氢或易裂解的醚或酰基残基,其中OR9-基团可以是α-或β-位, R2是游离的或官能改性的羟基,R 3和R 4各自独立地是氢,1-5个碳原子的烷基或氟,D是可以被1-5个碳原子的烷基取代的1-2个碳原子的亚烷基 原子,R5是氢或1-2个碳原子的烷基,或当D是1或2个碳原子的亚烷基时,R5与R6一起代表键,R6和R7各自独立地是氢或1-2碳的烷基 原子,其中当R 7(R 6)分别为1-2个碳原子的烷基或R 5和R 7 eac时,R 6(R 7)为卤素 h独立地为氢或1-2个碳原子的烷基,当D和R6一起形成通过(CH 2)1-3封闭的碳环,其中D为-CH 3且R 6为-CH 2 - ,当R 1为氢时, 其与碱的生理上相容的盐具有有价值的药理学性质,例如降血压和支气管扩张活性。

    5-Cyano-prostacyclin derivatives and use as medicines
    73.
    发明授权
    5-Cyano-prostacyclin derivatives and use as medicines 失效
    5-Cyano-prostacyclin衍生物用作药物

    公开(公告)号:US4364950A

    公开(公告)日:1982-12-21

    申请号:US317621

    申请日:1981-11-02

    摘要: 5-cyano-prostacyclins of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ; R.sub.2 and R.sub.3 each independently is (a) H, (b) C.sub.1-10 -alkyl, (c) C.sub.1-10 -alkyl substituted by halo, C.sub.1-4 -alkoxy or phenyl, 1-naphthyl or 2-naphthyl, each optionally substituted as defined below, (d) C.sub.4-10 -cycloalkyl, (e) C.sub.4-10 -cycloalkyl substituted by C.sub.1-4 -alkyl, (f) phenyl, 1-naphthyl or 2-naphthyl, (g) phenyl, 1-naphthyl or 2-naphthyl substituted by 1-3 halogen atoms, phenyl, 1-3 alkyl groups of 1-4 C atoms each, or a chloromethyl-, fluoromethyl-, trifluoromethyl-, carboxyl-, hydroxy- or alkoxy-group of 1-4 C atoms, or (h) an aromatic, 5- or 6-membered heterocyclic ring containing one hetero atom which is O, N or S, the remaining atoms being carbon; R.sub.3 also possibly being an acyl group of a C.sub.1-15 -hydrocarbon carboxylic or sulfonic acid;B is straight chain or branched alkylene of 2-10 C atoms;W is hydroxymethylene or ##STR2## wherein the OH group may be in the alpha or beta position, and is optionally modified by replacement of the H atom of the OH with an ether or acyl group which is conventional for such replacements in prostaglandins and which is readily cleavable at physiological pH's;R.sub.4 is hydroxy, optionally modified as described for W above;R.sub.5, R.sub.6, R.sub.7 and R.sub.8 each independently is hydrogen, alkyl of 1-5 C atoms or methoxy; andR.sub.9 is alkyl of 1-5 C atoms orfor compounds wherein R.sub.2 is H, the salts thereof with physiologically compatible bases have valuable pharmacalogical properties, e.g., hypertonic and bronchodilatory activities.

    摘要翻译: 其中R1是OR2或NHR3的式“IMAGE”的5-氰基 - 前列环素; R 2和R 3各自独立地为(a)H,(b)C 1-10 - 烷基,(c)被卤素,C 1-4 - 烷氧基或苯基,1-萘基或2-萘基取代的C 1-10 - 烷基, (d)C 4-10 - 环烷基,(e)被C 1-4 - 烷基取代的C 4-10 - 环烷基,(f)苯基,1-萘基或2-萘基,(g)苯基, 萘基或被1-3个卤素原子取代的2-萘基,苯基,1-4个C原子的1-3个烷基,或1个氯甲基 - ,氟甲基 - ,三氟甲基 - ,羧基 - ,羟基或烷氧基 -4个C原子,或(h)含有一个杂原子的芳族的5或6元杂环,它是O,N或S,其余的原子是碳; R3也可能是C1-15-烃羧酸或磺酸的酰基; B是2-10个C原子的直链或支链亚烷基; W是羟基亚甲基或其中OH基团可以在α或β位置,并且任选地通过用在前列腺素中这种替代物常规的醚或酰基取代OH的H原子来任意修饰,并且其是 在生理pH值下易于切割; R4是羟基,任选地按照上述W所述进行改性; R5,R6,R7和R8各自独立地为氢,1-5个C原子的烷基或甲氧基; 并且R 9为1-5个C原子的烷基,或对于其中R 2为H的化合物,其与生理上相容的碱的盐具有有价值的药理学性质,例如高渗和支气管扩张活性。

    Certain pyrrole analogs of prostacyclin derivatives
    74.
    发明授权
    Certain pyrrole analogs of prostacyclin derivatives 失效
    某些前列环素衍生物的吡咯类似物

    公开(公告)号:US4315013A

    公开(公告)日:1982-02-09

    申请号:US122794

    申请日:1980-02-19

    摘要: Prostane derivatives of the formula ##STR1## wherein R.sub.1 is (a) hydrogen, (b) C.sub.1-10 alkyl, (c) C.sub.1-10 alkyl substituted by halogen; C.sub.1-4 alkoxy; C.sub.6-10 aryl; C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group; di-C.sub.1-4 -alkylamino; or tri-C.sub.1-4 alkylammonium; (d) C.sub.4-10 cycloalkyl, (e) C.sub.4-10 cycloalkyl substituted by C.sub.1-4 alkyl, (f) C.sub.6-10 aryl, (g) C.sub.6-10 aryl substituted by 1-3 halogen atoms, a phenyl group, 1-3 C.sub.1-4 alkyl groups or a chloromethyl, fluoromethyl, trifluoromethyl, carboxy, hydroxy or C.sub.1-4 alkoxy group, or (h) an aromatic heterocycle of 5 or 6 ring atoms one of which is O, N or S;W is hydroxymethylene or RO-methylene; or ##STR2## wherein OH or OR is in the .alpha.-position and R is an in vivo hydrolyzable and physiologically acceptable ether or acyl group which is conventional for modifying OH groups in prostaglandins;R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently hydrogen or alkyl of 1-5 carbon atoms,R.sub.2 is OH or OR, R being as defined above,or, when R.sub.1 is H, a physiologically compatible salt thereof with a base.

    摘要翻译: 其中R 1为(a)氢,(b)C 1-10烷基,(c)被卤素取代的C 1-10烷基; C 1-4烷氧基; C6-10芳基; 被1-3个卤素原子取代的C 6-10芳基,苯基,1-3个C 1-4烷基或氯甲基,氟甲基,三氟甲基,羧基,羟基或C 1-4烷氧基; 二-C 1-4 - 烷基氨基; 或三-C 1-4烷基铵; (d)C 4-10环烷基,(e)被C 1-4烷基取代的C 4-10环烷基,(f)C 6-10芳基,(g)被1-3个卤素原子取代的C 6-10芳基,苯基, -3 C 1-4烷基或氯甲基,氟甲基,三氟甲基,羧基,羟基或C 1-4烷氧基,或(h)5或6个环原子的芳族杂环,其中一个为O,N或S; W是羟基亚甲基或RO-亚甲基; 或其中OH或OR位于α位且R是体内可水解和生理上可接受的醚或酰基,其是常规用于改变前列腺素中的OH基团; R 3,R 4,R 5和R 6各自独立地是氢或1-5个碳原子的烷基,R 2是OH或OR,R如上定义,或者当R 1是H时,其与碱的生理上相容的盐。

    Novel prostanoic acid derivatives and process for the preparation thereof
    75.
    发明授权
    Novel prostanoic acid derivatives and process for the preparation thereof 失效
    新型前列腺酸衍生物及其制备方法

    公开(公告)号:US4004020A

    公开(公告)日:1977-01-18

    申请号:US534483

    申请日:1974-12-19

    摘要: Prostaglandins of the formula ##STR1## wherein R.sub.1 is hydroxymethyl, carboxy, aryloxycarbonyl, alkoxycarbonyl of 1-8 carbon atoms in the alkoxy group, or the group -COO-CH.sub.2 -U-V wherein U is a direct C-C bond, carbonyl or carbonyloxy and V is phenyl substituted by phenyl, alkoxy of 1-2 carbon atoms or halogen; R.sub.2 is hydroxy and R.sub.3 is a hydrogen atom or R.sub.2 and R.sub.3 collectively are an oxygen atom; A is -CH.sub.2 -CH.sub.2 or trans-CH=CH; B is -CH.sub.2 -CH.sub.2 or CH=CH; one of R.sub.4 and R.sub.5 is hydroxy and the other is a hydrogen atom; R.sub.6 and R.sub.7 each are alkyl of 1-10 carbon atoms or collectively are alkylene of up to 7 carbon atoms and with 2-3 carbon atoms in the chain, phenylene or naphthylene; R.sub.8 is a hydrogen atom or alkyl of 1-5 carbon atoms; ##STR2## when R.sub.2 is hydroxy and R.sub.3 is a hydrogen atom or is ##STR3## or -CH=CH- when R.sub.2 and R.sub.3 collectively are an oxygen atom; or, when R.sub.1 is carboxy, a physiologically acceptable salt thereof with a base, possess the activity of the corresponding natural prostaglandins, including a luteolytic effect, and are useful in triggering abortions and syncronizing the conception cycle of mammals.

    摘要翻译: 其中R1是羟甲基,羧基,芳氧基羰基,烷氧基中1-8个碳原子的烷氧基羰基或基团-COO-CH2-UV,其中U是直接的CC键,羰基或羰基氧基和V 是被苯基,1-2个碳原子的烷氧基或卤素取代的苯基; R2是羟基,R3是氢原子,R2和R3一起是氧原子; A是-CH 2 -CH 2或反式-CH = CH; B是-CH 2 -CH 2或CH = CH; R4和R5之一是羟基,另一个是氢原子; R6和R7各自为1-10个碳原子的烷基,或者统称为至多7个碳原子的亚烷基,链中有2-3个碳原子,亚苯基或亚萘基; R8是氢原子或1-5个碳原子的烷基; 当R2和R3共同为氧原子时,当R 2为羟基且R 3为氢原子或者为或者-CH = CH-时, 或者,当R 1为羧基时,其与碱的生理上可接受的盐具有相应的天然前列腺素的活性,包括溶血性作用,并且可用于触发哺乳动物的受孕循环的流产和同步化。